KEY DETAILS
Patients and doctors are countering the president's fat drugs remark with reports of real, sustained weight loss in clinical practice.
GLP-1 prescriptions often lead to more follow-up visits, as Zocdoc data shows patients are 21% more likely to book another appointment.
Restaurants are reworking their menus to serve the roughly 30 million Americans now taking GLP-1 medications.
Gallup finds 11% of U.S. adults now use GLP-1 drugs, up from 3% in 2024, and a Toast survey shows this is changing how they order at restaurants.
GLP-1 use in one demographic jumped 24-fold, rising from 0.8% in 2018 to 1.9% in 2025, mainly for weight loss.
President Trump's offhand description of GLP-1 medications as 'fat drugs' drew an immediate response this week from the people who actually prescribe and take them. Doctors and patients pushed back with something harder to dismiss than a soundbite: documented, sustained weight loss in real clinical practice. The timing matters, because new data released the same day shows how far these drugs have spread, touching routine doctor visits and restaurant menus alike. For a reader managing treatment decisions, that gap between rhetoric and clinical reality is worth watching.
That pushback is not just a one-off defense. Physicians who prescribe semaglutide and tirzepatide report patients returning month after month with weight that has stayed off, not just dropped and rebounded. Patients themselves describe the medications in terms that go well beyond a quick fix, framing them as a durable change in how they manage their health. The president's comment reduced a complex clinical tool to a punchline, and the response from clinics suggests that framing does not match what doctors are actually recording in patient charts.
That ongoing relationship between patient and prescriber appears in the numbers, too. Zocdoc found that patients who book an initial GLP-1 visit are 21% more likely to schedule a follow-up appointment than patients booking for other reasons. That is not a small shift in behavior, and it suggests these prescriptions are reshaping the doctor-patient relationship rather than replacing it with a one-time transaction. A GLP-1 prescription, in other words, tends to open an ongoing conversation between doctor and patient, checking on dosage, side effects, and progress, rather than closing the visit out.
That same pattern of change that doctors are tracking is also reaching the restaurant industry. Roughly 30 million Americans are now taking GLP-1 medications, and that is a large enough group that restaurant chains can no longer treat them as a niche audience. Menus are being revised to offer smaller portions, higher protein options, and dishes built around satiety rather than volume. For an industry built on encouraging people to order more, this is a real adjustment, and it is happening because the customer base itself has changed.
Gallup's latest polling puts a number on how fast that customer base has grown. The share of U.S. adults taking a GLP-1 medication for weight loss rose to 11% in 2026, up from just 3% the year before. A companion survey from Toast, which asked 850 current GLP-1 users who eat out at least once a week what changed after they started the medication, found real shifts in ordering habits, not just smaller appetites in the abstract. Restaurants watching these numbers have reason to treat the trend as lasting rather than temporary, which helps explain why the menu changes described above are happening now rather than later.
The growth is not even across every group, and one figure stands out. Use of GLP-1 drugs in one demographic jumped 24-fold, climbing from 0.8% in 2018 to 1.9% in 2025, and the reason behind that increase is overwhelmingly weight loss rather than diabetes management. That pace of change, inside a group that historically had low uptake, says something about how quickly these medications have moved from niche prescription to mainstream habit. It also adds weight to the argument doctors are making against the president's comment: this is not a passing trend confined to one group, but a pattern repeating across different populations.
The clinical and political pictures here are telling different stories, and the data increasingly backs the clinical one. If you are currently taking a GLP-1 or considering one, it may help to pay attention to what is documented in appointments and surveys rather than in public commentary, and to ask your doctor directly how your own progress compares to what these reports describe. Restaurants are already adjusting to the scale of GLP-1 use, which is a sign that this shift is being treated as permanent by businesses that have no political stake in the debate. The number worth remembering is 30 million, since that is roughly how many Americans are living this story every day, regardless of what anyone calls it.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.